The combination therapy with sugemalimab showed a longer median PFS than chemotherapy alone for both squamous (8.3 vs. 4.8 months) and nonsquamous (9.6 vs. 5.8 months) NSCLC patients, independent of PD‐L1 expression levels. Here, CD274 is linked to non-small cell lung carcinoma.